Livio Trusolino

Dikutip oleh

	Semua	Sejak 2020
Kutipan	23273	11197
indeks-h	70	50
indeks-i10	120	97

2300

1150

575

1725

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202578 80 146 184 199 227 234 246 263 266 408 442 568 673 884 1020 1205 1437 1396 1739 1935 2270 2268 2196 2171 348

Akses publik

Lihat semua

85 artikel

2 artikel

tersedia

tidak tersedia

Berdasarkan pada mandat pendanaan

Pengarang bersama

Andrea BertottiUniversity of Torino - School of MedicineEmail yang diverifikasi di ircc.it
francesco sassiIRCC-University of Torino School of Medicine, Laboratory of Molecular Pharmacology ItalyEmail yang diverifikasi di ircc.it
Enzo MedicoProfessor of Histology, University of Torino and Head of the Laboratory of Oncogenomics, CandioloEmail yang diverifikasi di ircc.it
Salvatore SienaUniversità degli Studi di Milano e Ospedale Niguarda, Milano, ItalyEmail yang diverifikasi di unimi.it
Claudio IsellaIRCCEmail yang diverifikasi di ircc.it
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyEmail yang diverifikasi di ospedaleniguarda.it
Fortunato CiardielloProfessore di oncologia medica, seconda università di napoliEmail yang diverifikasi di unina2.it
Luca LazzariIFOM - FIRC Institute of Molecular OncologyEmail yang diverifikasi di ifom.eu
Jos JonkersProfessor at Leiden University and group leader at Netherlands Cancer Institute, Oncode InstituteEmail yang diverifikasi di nki.nl
Simona CorsoUniversity of TorinoEmail yang diverifikasi di ircc.it
Charlotte RolnyAssociate professor of tumor biology, PI at Lund University and Karolinska Institutet, SwedenEmail yang diverifikasi di med.lu.se
Alessandro AMOREOspedale Regina Margherita Torino, Università degli studi TorinoEmail yang diverifikasi di unito.it
Massimiliano MazzoneGroup Leader, Vesalius Research CenterEmail yang diverifikasi di vib-kuleuven.be
Lorenzo CapussottiChief of the Surgical Deparment- Ospedale Mauriziano "Umberto I" TorinoEmail yang diverifikasi di mauriziano.it
Andrea CasazzaDirector Biology @ Montis Bioscience, BelgiumEmail yang diverifikasi di montisbio.com
Guido SeriniProfessor, University of Torino School of Medicine | Candiolo Cancer Institute IRCCSEmail yang diverifikasi di ircc.it
Dario RiberoDirigente Medico I livello, Divisione di Chirurgia Generale ed Oncologica, Ospedale Mauriziano Umberto IEmail yang diverifikasi di mauriziano.it
Lodewyk WesselsProfessor of Computational Cancer BiologyEmail yang diverifikasi di nki.nl
Giuseppe Bassoprofessor of pediatrics university paduaEmail yang diverifikasi di unipd.it
Antonio PalumboUniversità di Torino; Torino ItalyEmail yang diverifikasi di unito.it

Ikuti

Livio Trusolino

Professor, University of Torino School of Medicine, Italy

Email yang diverifikasi di ircc.it - Beranda

Targeted anti-cancer therapies animal models oncogenic signal transduction pathways


Judul Urutkan menurut kutipan Urutkan menurut tahun Urutkan menurut judul	Dikutip oleh Dikutip oleh	Tahun
Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014	1785	2014
MET signalling: principles and functions in development, organ regeneration and cancer L Trusolino, A Bertotti, PM Comoglio Nature reviews Molecular cell biology 11 (12), 834-848, 2010	1382	2010
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019	1196	2019
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016	1054	2016
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011	1046	2011
Drug development of MET inhibitors: targeting oncogene addiction and expedience PM Comoglio, S Giordano, L Trusolino Nature reviews Drug discovery 7 (6), 504-516, 2008	984	2008
Scatter-factor and semaphorin receptors: cell signalling for invasive growth L Trusolino, PM Comoglio Nature reviews cancer 2 (4), 289-300, 2002	911	2002
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013	725	2013
Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254-268, 2017	723	2017
Stromal contribution to the colorectal cancer transcriptome C Isella, A Terrasi, SE Bellomo, C Petti, G Galatola, A Muratore, A Mellano, ... Nature genetics 47 (4), 312-319, 2015	669	2015
A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth L Trusolino, A Bertotti, PM Comoglio Cell 107 (5), 643-654, 2001	565	2001
The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015	495	2015
The Met tyrosine kinase receptor in development and cancer A Gentile, L Trusolino, PM Comoglio Cancer and metastasis reviews 27, 85-94, 2008	393	2008
Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019	389	2019
EGFR Blockade Reverts Resistance to KRAS^G12C Inhibition in Colorectal Cancer V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ... Cancer discovery 10 (8), 1129-1139, 2020	371	2020
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014	358	2014
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy PM Comoglio, L Trusolino, C Boccaccio Nature Reviews Cancer 18 (6), 341-358, 2018	335	2018
Interactions between growth factor receptors and adhesion molecules: breaking the rules PM Comoglio, C Boccaccio, L Trusolino Current opinion in cell biology 15 (5), 565-571, 2003	327	2003
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. G Tripodi, F Valtorta, L Torielli, E Chieregatti, S Salardi, L Trusolino, ... The Journal of clinical investigation 97 (12), 2815-2822, 1996	322	1996
HER2 activating mutations are targets for colorectal cancer treatment SM Kavuri, N Jain, F Galimi, F Cottino, SM Leto, G Migliardi, ... Cancer discovery 5 (8), 832-841, 2015	311	2015

Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.

Artikel 1–20

Kutipan per tahun

Kutipan duplikat

Kutipan yang digabung

Tambahkan pengarang bersamaPengarang bersama

Ikuti

Dikutip oleh

Pengarang bersama